Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 8/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7913181 | 0.91 | ADRA2A (0.43) | CHRM2CHRM1CHRM3CHRM4CYP3A4 | |
| SCHEMBL8524436 | 0.91 | CHRM2 (0.46) | CHRM2CHRM1CHRM3CHRM4CYP3A4 | |
| SCHEMBL8578195 | 0.91 | CYP3A4 (0.43) | CHRM2CHRM1CHRM3CHRM4CYP3A4 | |
| SCHEMBL3364418 | 0.85 | PTGDR2 (0.38) | CHRM2CHRM1CHRM3CHRM4CYP3A4 | |
| SCHEMBL7914136 | 0.84 | PTGDR2 (0.40) | CHRM2CHRM1CHRM3CHRM4CYP3A4 | |
| SCHEMBL8475476 | 0.81 | PTGDR2 (0.36) | CHRM2CHRM1CHRM3CHRM4CYP3A4 | |
| SCHEMBL290175 | 0.80 | TSHR (0.45) | CHRM1KCNH2CYP1A2CYP2D6ADRA2A | |
| SCHEMBL8473282 | 0.79 | PTGDR2 (0.35) | CHRM2CHRM1CHRM3CHRM4CYP3A4 | |
| SCHEMBL25188997 | 0.79 | SLC6A2 (0.43) | CHRM1KCNH2CYP1A2CYP2D6ADRA2A | |
| SCHEMBL1610659 | 0.77 | CHRM2 (0.53) | CHRM2CHRM1CHRM3CHRM4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432446-B2 | ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF 4-ETHYLAMINO-2-BUTYNYL CYCLOHEXYL-PHENYLGLYCOLATE AND/ OR ONE OR MORE OPTICALLY ACTIVE ISOMERS, AND SALTS TO TREAT DISORDERS INVOLVING THE URETHROGENITAL TRACT | BRIDGE PHARMA, INC. | 2002-08-13 | — | — | US | claimed |
| EP-4676445-A1 | MICROSPHERE FORMULATIONS AND METHODS OF PREPARATION THEREOF | Lotus Biopharma Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024186598-A1 | MICROSPHERE FORMULATIONS AND METHODS OF PREPARATION THEREOF | LOTUS BIOPHARMA INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| EP-1286591-B1 | TREATING SMOOTH MUSCLE HYPERACTIVITY WITH (R)-OXYBUTYNIN AND (R)- DESETHYLOXYBUTYNIN | WATSON PHARMACEUTICALS INC (US) | 2010-10-06 | — | — | EP | disclosed |
| EP-1286591-A4 | TREATING SMOOTH MUSCLE HYPERACTIVITY WITH (R)-OXYBUTYNIN AND (R)- DESETHYLOXYBUTYNIN | WATSON PHARMACEUTICALS INC (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1455776-A4 | A NON-ARRHYTHMOGENIC METABOLITE OF OXYBUTYNIN | BRIDGE PHARMA INC (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1455776-A1 | A NON-ARRHYTHMOGENIC METABOLITE OF OXYBUTYNIN | Bridge Pharma, Inc. (US) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003066042-A1 | A NON-ARRHYTHMOGENIC METABOLITE OF OXYBUTYNIN | BRIDGE PHARMA, INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-1286591-A1 | TREATING SMOOTH MUSCLE HYPERACTIVITY WITH (R)-OXYBUTYNIN AND (R)- DESETHYLOXYBUTYNIN | Watson Pharmaceuticals, Inc. (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6432446-B2 | ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF 4-ETHYLAMINO-2-BUTYNYL CYCLOHEXYL-PHENYLGLYCOLATE AND/ OR ONE OR MORE OPTICALLY ACTIVE ISOMERS, AND SALTS TO TREAT DISORDERS INVOLVING THE URETHROGENITAL TRACT | BRIDGE PHARMA, INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020002201-A1 | Non-arrhythmogenic metabolite of oxybutynin | BRIDGE PHARMA, INC. | 2002-01-03 | — | — | US | disclosed |
| WO-2001093683-A1 | TREATING SMOOTH MUSCLE HYPERACTIVITY WITH (R)-OXYBUTYNIN AND (R)- DESETHYLOXYBUTYNIN | WATSON PHARMACEUTICALS, INC. (US) | 2001-12-13 | — | — | WO | disclosed |
| US-6207852-B1 | THERAPY FOR INCONTINENCE; CROHN'S DISEASE; MUSCLE RELAXANTS | BRIDGE PHARMA, INC. | 2001-03-27 | — | — | US | disclosed |
| US-6123961-A | WITHOUT CARDIOVASCULAR DEPRESSING ACTIVITY SIDE EFFECT, BY ADMINISTERING R(-)-4-DIETHYLAMINO-2-BUTYNYL CYCLOHEXYLPHENYLGLYCOLATE OR SALT, FREE OF ITS CORRESPONDING S-ENANTIOMER | BRIDGE PHARMA, INC. (US) | 2000-09-26 | — | — | US | disclosed |
| US-6123961-A | WITHOUT CARDIOVASCULAR DEPRESSING ACTIVITY SIDE EFFECT, BY ADMINISTERING R(-)-4-DIETHYLAMINO-2-BUTYNYL CYCLOHEXYLPHENYLGLYCOLATE OR SALT, FREE OF ITS CORRESPONDING S-ENANTIOMER | BRIDGE PHARMA, INC. (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0915826-A4 | SMOOTH MUSCLE SPASMOLYTIC AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF | BRIDGE PHARMA INC (US) | 1999-12-29 | — | — | EP | disclosed |
| EP-0915826-A1 | SMOOTH MUSCLE SPASMOLYTIC AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF | Bridge Pharma, Inc. (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998000390-A1 | SMOOTH MUSCLE SPASMOLYTIC AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF | BRIDGE PHARMA, INC. (US) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002201-A1 | Non-arrhythmogenic metabolite of oxybutynin | TNNT2, TNNC1, CYP11B1 | CHRM2 1183/4885CHRM1 1096/4885CHRM3 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.